ARK Genomic Price To Earning vs. Price To Book

ARKG Etf  USD 25.04  0.85  3.51%   
Based on the measurements of profitability obtained from ARK Genomic's financial statements, ARK Genomic Revolution may not be well positioned to generate adequate gross income at the present time. It has a very high likelihood of underperforming in June. Profitability indicators assess ARK Genomic's ability to earn profits and add value for shareholders.
For ARK Genomic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ARK Genomic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ARK Genomic Revolution utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ARK Genomic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ARK Genomic Revolution over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ARK Genomic Revolution Price To Book vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ARK Genomic's current stock value. Our valuation model uses many indicators to compare ARK Genomic value to that of its competitors to determine the firm's financial worth.
ARK Genomic Revolution is the top ETF in price to earning as compared to similar ETFs. It is the top ETF in price to book as compared to similar ETFs fabricating about  0.08  of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for ARK Genomic Revolution is roughly  12.84 . Comparative valuation analysis is a catch-all model that can be used if you cannot value ARK Genomic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ARK Genomic's Etf. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ARK Genomic's earnings, one of the primary drivers of an investment's value.

ARK Price To Book vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

ARK Genomic

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
41.86 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

ARK Genomic

P/B

 = 

MV Per Share

BV Per Share

 = 
3.26 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

ARK Price To Book Comparison

ARK Genomic is currently under evaluation in price to book as compared to similar ETFs.

ARK Genomic Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ARK Genomic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ARK Genomic will eventually generate negative long term returns. The profitability progress is the general direction of ARK Genomic's change in net profit over the period of time. It can combine multiple indicators of ARK Genomic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States.

ARK Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ARK Genomic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ARK Genomic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ARK Genomic's important profitability drivers and their relationship over time.

Use ARK Genomic in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARK Genomic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARK Genomic will appreciate offsetting losses from the drop in the long position's value.

ARK Genomic Pair Trading

ARK Genomic Revolution Pair Trading Analysis

The ability to find closely correlated positions to ARK Genomic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARK Genomic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARK Genomic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARK Genomic Revolution to buy it.
The correlation of ARK Genomic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARK Genomic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARK Genomic Revolution moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARK Genomic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ARK Genomic position

In addition to having ARK Genomic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Munis Funds Thematic Idea Now

Munis Funds
Munis Funds Theme
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:
Check out Trending Equities.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
To fully project ARK Genomic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ARK Genomic Revolution at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ARK Genomic's income statement, its balance sheet, and the statement of cash flows.
Potential ARK Genomic investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ARK Genomic investors may work on each financial statement separately, they are all related. The changes in ARK Genomic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ARK Genomic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.